CCN1 antibody targets the Cellular Communication Network Factor 1 (CCN1), also known as CYR61 (Cysteine-Rich Angiogenic Inducer 61), a matricellular protein belonging to the CCN family (CCN1-6). CCN1 is involved in diverse cellular processes, including proliferation, adhesion, migration, differentiation, and apoptosis, by interacting with integrins, heparan sulfate proteoglycans, and growth factor receptors. It plays critical roles in development, tissue repair, angiogenesis, inflammation, and tumorigenesis. Dysregulation of CCN1 is linked to pathologies such as fibrosis, atherosclerosis, rheumatoid arthritis, and cancers (e.g., breast, liver, and glioblastoma).
CCN1 antibodies are essential tools for detecting and studying the protein's expression, localization, and function in vitro and in vivo. They enable techniques like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and flow cytometry. Researchers use these antibodies to explore CCN1's dual roles in cancer—promoting tumor progression via angiogenesis and metastasis or suppressing it through senescence and apoptosis, depending on context. Commercial CCN1 antibodies are typically raised in rabbits or mice against specific epitopes, with validation in knockout models or siRNA-treated samples to ensure specificity. Applications span basic research, biomarker discovery, and therapeutic target validation. However, challenges include cross-reactivity with other CCN proteins due to structural homology, emphasizing the need for rigorous validation. Major suppliers include R&D Systems, Abcam, and Santa Cruz Biotechnology.